Company Overview
Nurix Therapeutics, Inc. operates as a clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecule and antibody therapies designed to treat cancer, inflammatory conditions, and other diseases. The company functions within the Healthcare sector, specifically the Biotechnology industry, where it focuses on advancing proprietary drug candidates through various stages of clinical evaluation. Currently, the firm employs a workforce of 317 individuals and maintains a total market capitalization of $1.52B. While the company has generated $83.98M in annual revenue, the market cap suggests a significant valuation premium relative to its current earnings generation, reflecting investor expectations for future clinical success rather than current profitability.
Financial Health
The company reported revenue of $83.98M over the trailing twelve months, yet it recorded a net income of -$264,456,992 and an EBITDA of -$277,526,016, indicating a substantial gap between top-line sales and bottom-line profitability driven by high operating expenses typical of clinical-stage development. Free cash flow stands at -$143,989,248, which demonstrates that the company is currently burning cash to fund its research and development activities rather than generating liquidity from operations. The gross margin is reported at -277.4%, the operating margin at -612.0%, and the profit margin at 0.0%, figures that highlight the intense cost structure associated with bringing novel therapies to market before reaching commercial scale. In terms of leverage, Nurix holds $592.94M in cash against $55.73M in debt, resulting in a debt-to-equity ratio of 10.34, which suggests a balance sheet heavily weighted toward equity financing despite the presence of some debt obligations. The current ratio of 7.02 indicates a robust short-term liquidity position, providing ample coverage for immediate obligations despite the negative cash flow. Additionally, the return on equity is -49.6% and the return on assets is -26.3%, metrics that reveal that management has not yet achieved positive returns on shareholder capital or asset base due to the pre-revenue nature of the business model.
Valuation Assessment
Valuation metrics for Nurix Therapeutics show a trailing P/E ratio that is N/A due to negative earnings, while the forward P/E is listed at -4.89, implying that the market is pricing in future earnings potential that has not yet materialized in the current financial statements. The price-to-book ratio is 2.79, suggesting that the market values the company at nearly three times its net asset value, a premium often found in biotech firms with valuable intellectual property portfolios. Alternative valuation multiples include a price-to-sales ratio of 18.09 and an EV/EBITDA of -3.41, which indicate that investors are primarily valuing the company based on its revenue generation and pipeline potential rather than current earnings power. The stock has traded between a 52-week low of $8.18 and a 52-week high of $22.50, with the current valuation context requiring analysis of where the price sits within this established volatility range. The beta of 2.02 signifies that the stock exhibits high price volatility, moving with approximately double the magnitude of the broader market index, which introduces significant risk for those holding the position during periods of market fluctuation.
Growth & Income
Revenue growth over the last year was recorded at 2.2%, whereas earnings growth is listed as N/A because the company continues to report losses, meaning that earnings are not growing in the traditional sense as revenue expansion is currently the primary driver of activity. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash flow is being retained to fund operations and clinical trials rather than distributed to shareholders. This reinvestment strategy is standard for clinical-stage biotechnology firms that prioritize funding drug development over providing income returns to investors. Consequently, the overall growth and income profile is defined by moderate revenue expansion coupled with significant cash consumption and a lack of current income distribution, relying entirely on future asset monetization for long-term value creation.